As a clinical researcher, she has been involved in the development of clinical trials for the treatment of acute myeloid leukemia (AML) and GVHD. Specifically, she has implemented a trial for the treatment of AML in elderly patients using a novel induction regimen based on the mechanism of epigenetic priming. In addition, she has an interest in novel targets for the treatment of chronic GVHD, such as JAK-STAT pathway inhibition, and has implemented trials in this area in collaboration with the Chronic GVHD Research Group in the Experimental Transplantation and Immunology Branch of the National Cancer Institute. Her clinical interests also include development of a Chronic GVHD and Long-Term Follow Up program for the stem cell transplant program at UPMC. Dr. Im has also been heavily involved in medical education for residents and fellows, and is now the Program Director for the Hematology/Oncology Fellowship and the Subspecialty Education Coordinator for the Internal Medicine Residency.
Dr. Im’s clinical focus is in hematologic malignancies and hematopoietic stem cell transplantation. Her current research interests are focused in the area of graft-versus-host disease (GVHD), a complication of stem cell transplant, as well as in late effects in transplant survivors.
- BA, Williams College, MA, 2001
- MD, State University of New York Stony Brook School of Med, 2006
- Residency, Internal Medicine, University of Pittsburgh Medical Center, 2009
- Fellowship, Hematology/Oncology, University of Pittsburgh Medical Center, 2013
- Fellowship, Blood and Marrow Transplant, University of Pittsburgh Medical Center, 2013
Education & Training
Im A, Mitchell SA, Steinberg SM, Curtis L, Berger A, Baird K, Kuzmina Z, Joe G, Comis LE, Juckett M, Avila D, Baruffaldi J, Masuch L, Pirsl F, Pavletic SZ. Prevalence and determinants of fatigue in patients with moderate to severe chronic graft-versus-host disease. Bone Marrow Transplant. 2016; 51(5): 705-12.
Im A, Raptis A, Hou J, Tompkins C, Winfield M, Guay M, Boyiadzis M, Agha M. Hypomethylating agents for relapse after allogeneic hematopoietic cell transplantation in myeloid malignancies: a case series and review of the literature. Acta Haematology. 2016; 135(4): 232-237.
Im A, Amjad A, Agha M, Raptis A, Hou JZ, Farah R, Lim S, Sehgal A, Dorritie KA, Redner FL, McLaughlin B, Shuai Y, Duggal S, Boyiadzis M. Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse. Oncology Research. 2016
Im A, Pavletic SZ. Deciphering the Mystery: Extracorporeal Photopheresis in Graft-versus-Host Disease. Biology of Blood Marrow Transplant. 2015; 21(11): 1861-2.
Im A, Sehgal AR, Carroll MP, Smith BD, Johnson DE, Boyiadzis M. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia. 2014; 28(9): 1774-83.
Im A, Appleman LJ. Mifepristone: pharmacology and clinical impact in reproductive medicine, endocrinology and oncology. Expert Opinion on Pharmacotherapy. 2010; 3: 481-8.
Taioli E, Im A, Xu X, Veenstra TD, Ahrendt G, Garte S. Comparisons of estrogens and estrogen metabolites in human breast tissue and urine. Reproductive Biology and Endocrinology. 2010; 96: 743-747.
Im A, Vogel VG, Ahrendt G, Lloyd S, Ragin C, Garte S, Taioli E. Urinary estrogen metabolites in women at high risk for breast cancer. Carcinogenesis. 2009; 9: 1532-5.
- Selected for the ECOG-ACRIN Young Investigators Symposium, 2014
